BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, said that it has commenced an underwritten public offering of $250 million of shares of its common stock.
BridgeBio also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by BridgeBio.
J.P. Morgan, Cantor Fitzgerald & Co. and Mizuho are acting as joint book-running managers for the proposed offering. Raymond James is acting as lead manager.
BBIO closed Monday's regular trading at $32.35 down $3.28 or 9.19%. In the after-hours trading, the stock further dropped $1.09 or 3.38%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.